{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:55:55Z","timestamp":1790052955798,"version":"4.0.1"},"reference-count":70,"publisher":"The Fukushima Society of Medical Science","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FJMS","Fukushima J. Med. Sci."],"published-print":{"date-parts":[[2023]]},"DOI":"10.5387\/fms.2023-08","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T22:13:37Z","timestamp":1686348817000},"page":"85-93","source":"Crossref","is-referenced-by-count":6,"title":["Tau positron emission tomography in patients with cognitive impairment and suspected Alzheimer\u2019s disease"],"prefix":"10.5387","volume":"69","author":[{"given":"Hiroshi","family":"Matsuda","sequence":"first","affiliation":[{"name":"Department of Biofunctional Imaging, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tensho","family":"Yamao","sequence":"additional","affiliation":[{"name":"Department of Radiological Sciences, School of Health Sciences, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3342","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Jack CR Jr, Bennett DA, Blennow K, <i>et al<\/i>. Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement, <b>14<\/b>:535-562, 2018.","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Nelson PT, Head E, Schmitt FA, <i>et al<\/i>. Alzheimer\u2019s disease is not \u201cbrain aging\u201d: neuropathological, genetic, and epidemiological human studies. Acta Neuropathol, <b>121<\/b>:571-587, 2011.","DOI":"10.1007\/s00401-011-0826-y"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Serrano-Pozo A, Qian J, Monsell SE, <i>et al<\/i>. Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol, <b>75<\/b>:597-601, 2014.","DOI":"10.1002\/ana.24125"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Nelson PT, Alafuzoff I, Bigio EH, <i>et al<\/i>. Correlation of Alzheimer disease neuropathologic changes with cognitive status:a review of the literature. J Neuropathol Exp Neurol, <b>71<\/b>:362-381, 2012.","DOI":"10.1097\/NEN.0b013e31825018f7"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Jack CR Jr, Bennett DA, Blennow K, <i>et al<\/i>. A\/T\/N:An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology, <b>87<\/b>:539-547, 2016.","DOI":"10.1212\/WNL.0000000000002923"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Matsuda H, Shigemoto Y, Sato N. Neuroimaging of Alzheimer\u2019s disease:focus on amyloid and tau PET. Jpn J Radiol, <b>37<\/b>:735-749, 2019.","DOI":"10.1007\/s11604-019-00867-7"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Rabinovici GD, Gatsonis C, Apgar C, <i>et al<\/i>. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA, <b>321<\/b>:1286-1294, 2019.","DOI":"10.1001\/jama.2019.2000"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Matsuda H, Ito K, Ishii K, <i>et al<\/i>. Quantitative evaluation of <sup>18<\/sup>F-Flutemetamol PET in patients with cognitive impairment and suspected Alzheimer\u2019s disease:a multicenter study. Front Neurol, <b>11<\/b>:578753, 2021.","DOI":"10.3389\/fneur.2020.578753"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Matsuda H, Okita K, Motoi Y, <i>et al<\/i>. Clinical impact of amyloid PET using <sup>18<\/sup>F-florbetapir in patients with cognitive impairment and suspected Alzheimer\u2019s disease:a multicenter study. Ann Nucl Med, <b>36<\/b>:1039-1049, 2022","DOI":"10.1007\/s12149-022-01792-y"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Beyer L, Brendel M. Imaging of tau pathology in neurodegenerative diseases:an update. Semin Nucl Med, <b>51<\/b>:253-263, 2021.","DOI":"10.1053\/j.semnuclmed.2020.12.004"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Cassinelli Petersen G, Roytman M, Chiang GC, Li Y, Gordon ML, Franceschi AM. Overview of tau PET molecular imaging. Curr Opin Neurol, <b>35<\/b>:230-239, 2022.","DOI":"10.1097\/WCO.0000000000001035"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci, <b>17<\/b>:5-21, 2016.","DOI":"10.1038\/nrn.2015.1"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Zhang Y, Wu KM, Yang L, <i>et al<\/i>. Tauopathies:new perspectives and challenges. Mol Neurodegeneration, <b>17<\/b>:28, 2022.","DOI":"10.1186\/s13024-022-00533-z"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Shoghi-Jadid K, Small GW, Agdeppa ED, <i>et al<\/i>. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry, <b>10<\/b>:24-35, 2002.","DOI":"10.1097\/00019442-200201000-00004"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Maruyama M, Shimada H, Suhara T, <i>et al<\/i>. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron, <b>79<\/b>:1094-1108, 2013.","DOI":"10.1016\/j.neuron.2013.07.037"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hashimoto H, Kawamura K, Takei M, <i>et al<\/i>. Identification of a major radiometabolite of [<sup>11<\/sup>C]PBB3. Nucl Med Biol, <b>42<\/b>:905-910, 2015.","DOI":"10.1016\/j.nucmedbio.2015.08.006"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Okamura N, Furumoto S, Harada R, <i>et al<\/i>. Novel <sup>18<\/sup>F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med, <b>54<\/b>:1420-1427, 2013.","DOI":"10.2967\/jnumed.112.117341"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Harada R, Okamura N, Furumoto S, <i>et al<\/i>. <sup>18<\/sup>F-THK5351:A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease. J Nucl Med, <b>57<\/b>:208-214, 2016.","DOI":"10.2967\/jnumed.115.164848"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ng KP, Pascoal TA, Mathotaarachchi S, <i>et al<\/i>. Monoamine oxidase B inhibitor, selegiline, reduces <sup>18<\/sup>F-THK5351 uptake in the human brain. Alzheimers Res Ther, <b>9<\/b>:25, 2017.","DOI":"10.1186\/s13195-017-0253-y"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Marqui\u00e9 M, Normandin MD, Vanderburg CR, <i>et al<\/i>. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol, <b>78<\/b>:787-800, 2015.","DOI":"10.1002\/ana.24517"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Mattay VS, Fotenos AF, Ganley CJ, Marzella L. Brain tau Imaging:Food and Drug Administration approval of <sup>18<\/sup>F-Flortaucipir Injection. J Nucl Med, <b>61<\/b>:1411-1412, 2020.","DOI":"10.2967\/jnumed.120.252254"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Jie CVML, Treyer V, Schibli R, Mu L. Tauvid\u2122: The first FDA-approved PET tracer for imaging tau pathology in Alzheimer\u2019s disease. Pharmaceuticals (Basel), <b>14<\/b>:110, 2021.","DOI":"10.3390\/ph14020110"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Sander K, Lashley T, Gami P, <i>et al<\/i>. Characterization of tau positron emission tomography tracer [<sup>18<\/sup>F]AV-1451 binding to postmortem tissue in Alzheimer\u2019s disease, primary tauopathies, and other dementias. Alzheimers Dement, <b>12<\/b>:1116-1124, 2016.","DOI":"10.1016\/j.jalz.2016.01.003"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Lowe VJ, Curran G, Fang P, <i>et al<\/i>. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun, <b>4<\/b>:58, 2016.","DOI":"10.1186\/s40478-016-0315-6"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Marqui\u00e9 M, Verwer EE, Meltzer AC, <i>et al<\/i>. Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson\u2019s case. Acta Neuropathol Commun, <b>5<\/b>:75, 2017.","DOI":"10.1186\/s40478-017-0482-0"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Lee CM, Jacobs HIL, Marqui\u00e9 M, <i>et al<\/i>. <sup>18<\/sup>F-Flortaucipir Binding in Choroid Plexus:Related to Race and Hippocampus Signal. J Alzheimers Dis, <b>62<\/b>:1691-1702, 2018.","DOI":"10.3233\/JAD-170840"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Ikonomovic MD, Uryu K, Abrahamson EE, <i>et al<\/i>. Alzheimer\u2019s pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol, <b>190<\/b>:192-203, 2004.","DOI":"10.1016\/j.expneurol.2004.06.011"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Choi JY, Cho H, Ahn SJ, <i>et al<\/i>. Off-Target <sup>18<\/sup>F-AV-1451 Binding in the Basal Ganglia Correlates with Age-Related Iron Accumulation. J Nucl Med, <b>59<\/b>:117-120, 2018.","DOI":"10.2967\/jnumed.117.195248"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Ikonomovic MD, Abrahamson EE, Price JC, Mathis CA, Klunk WE. [F-18]AV-1451 positron emission tomography retention in choroid plexus: More than \u201coff-target\u201d binding. Ann Neurol, <b>80<\/b>:307-308, 2016.","DOI":"10.1002\/ana.24706"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Vermeiren C, Motte P, Viot D, Mairet-Coello G, <i>et al<\/i>. The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases. Mov Disord, <b>33<\/b>:273-281, 2018.","DOI":"10.1002\/mds.27271"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Hansen AK, Brooks DJ, Borghammer P. MAO-B Inhibitors do not block in vivo Flortaucipir([<sup>18<\/sup>F]-AV-1451) binding. Mol Imaging Biol, <b>20<\/b>:356-360, 2018.","DOI":"10.1007\/s11307-017-1143-1"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Yap SY, Frias B, Wren MC, <i>et al<\/i>. Discriminatory ability of next-generation tau PET tracers for Alzheimer\u2019s disease. Brain, <b>144<\/b>:2284-2290, 2021.","DOI":"10.1093\/brain\/awab120"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Honer M, Gobbi L, Knust H, <i>et al<\/i>. Preclinical Evaluation of <sup>18<\/sup>F-RO6958948, <sup>11<\/sup>C-RO6931643, and <sup>11<\/sup>C-RO6924963 as Novel PET Radiotracers for Imaging Tau Aggregates in Alzheimer Disease. J Nucl Med,<b> 59<\/b>:675-681, 2018.","DOI":"10.2967\/jnumed.117.196741"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Wong DF, Comley RA, Kuwabara H, <i>et al<\/i>. Characterization of 3 Novel Tau Radiopharmaceuticals, <sup>11<\/sup>C-RO-963, <sup>11<\/sup>C-RO-643, and <sup>18<\/sup>F-RO-948, in Healthy Controls and in Alzheimer Subjects. J Nucl Med, <b>59<\/b>:1869-1876, 2018.","DOI":"10.2967\/jnumed.118.209916"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Kuwabara H, Comley RA, Borroni E, <i>et al<\/i>. Evaluation of <sup>18<\/sup>F-RO-948 PET for Quantitative Assessment of Tau Accumulation in the Human Brain. J Nucl Med, <b>59<\/b>:1877-1884, 2018.","DOI":"10.2967\/jnumed.118.214437"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Sanabria Boh\u00f3rquez S, Marik J, Ogasawara A, <i>et al<\/i>. [<sup>18<\/sup>F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging, <b>46<\/b>:2077-2089, 2019.","DOI":"10.1007\/s00259-019-04399-0"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Blennow K, Chen C, Cicognola C, <i>et al<\/i>. Cerebrospinal fluid tau fragment correlates with tau PET:a candidate biomarker for tangle pathology. Brain, <b>143<\/b>:650-660, 2020.","DOI":"10.1093\/brain\/awz346"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Kroth H, Oden F, Molette J, <i>et al<\/i>. Discovery and preclinical characterization of [<sup>18<\/sup>F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer\u2019s disease and other tauopathies. Eur J Nucl Med Mol Imaging, <b>46<\/b>:2178-2189, 2019.","DOI":"10.1007\/s00259-019-04397-2"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Mormino EC, Toueg TN, Azevedo C, <i>et al<\/i>. Tau PET imaging with <sup>18<\/sup>F-PI-2620 in aging and neurodegenerative diseases. Eur J Nucl Med Mol Imaging, <b>48<\/b>:2233-2244, 2021.","DOI":"10.1007\/s00259-020-04923-7"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Baker SL, Provost K, Thomas W, <i>et al<\/i>. Evaluation of [<sup>18<\/sup>F]-JNJ-64326067-AAA tau PET tracer in humans. J Cereb Blood Flow Metab, <b>41<\/b>:3302-3313, 2021.","DOI":"10.1177\/0271678X211031035"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Tagai K, Ono M, Kubota M, <i>et al<\/i>. High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer\u2019s and Non-Alzheimer\u2019s Disease Tauopathies. Neuron, <b>109<\/b>:42-58.e8, 2021.","DOI":"10.1016\/j.neuron.2020.09.042"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Ishizuchi K, Takizawa T, Tezuka T, <i>et al<\/i>. A case of progressive supranuclear palsy with predominant cerebellar ataxia diagnosed by [<sup>18<\/sup>F]PM-PBB3 tau PET. J Neurol Sci, <b>425<\/b>:117440, 2021.","DOI":"10.1016\/j.jns.2021.117440"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Zhou Y, Li J, Nordberg A, \u00c5gren H. Dissecting the binding profile of PET tracers to corticobasal degeneration tau fibrils. ACS Chem Neurosci, <b>12<\/b>:3487-3496, 2021.","DOI":"10.1021\/acschemneuro.1c00536"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Mishra SK, Yamaguchi Y, Higuchi M, Sahara N. Pick\u2019s tau fibril shows multiple distinct PET probe binding sites:insights from computational modelling. Int J Mol Sci, <b>22<\/b>:349, 2020.","DOI":"10.3390\/ijms22010349"},{"key":"45","doi-asserted-by":"publisher","unstructured":"45. Knight AC, Morrone CD, Varlow C, Yu WH, McQuade P, Vasdev N. Head-to-head comparison of tau-PET radioligands for imaging TDP-43 in post-mortem ALS brain. Mol Imaging Biol, 2022;10.1007\/s11307-022-01779-1.","DOI":"10.1007\/s11307-022-01779-1"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Perez-Soriano A, Arena JE, Dinelle K, <i>et al<\/i>. PBB3 imaging in Parkinsonian disorders:Evidence for binding to tau and other proteins. Mov Disord, <b>32<\/b>:1016-1024, 2017.","DOI":"10.1002\/mds.27029"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Koga S, Ono M, Sahara N, Higuchi M, Dickson DW. Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to \u03b1-synuclein pathology. Mov Disord, <b>32<\/b>:884-892, 2017.","DOI":"10.1002\/mds.27013"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Walji AM, Hostetler ED, Selnick H, <i>et al<\/i>. Discovery of 6-(Fluoro-(<sup>18<\/sup>)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(<sup>18<\/sup>)F]-MK-6240):A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs). J Med Chem, <b>59<\/b>:4778-4789, 2016.","DOI":"10.1021\/acs.jmedchem.6b00166"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Leuzy A, Pascoal TA, Strandberg O, <i>et al<\/i>. A multicenter comparison of [<sup>18<\/sup>F]flortaucipir, [<sup>18<\/sup>F]RO948, and [<sup>18<\/sup>F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. Eur J Nucl Med Mol Imaging, <b>48<\/b>:2295-2305, 2021.","DOI":"10.1007\/s00259-021-05401-4"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Hostetler ED, Walji AM, Zeng Z, <i>et al<\/i>. Preclinical characterization of <sup>18<\/sup>F-MK-6240, a promising PET tracer for In vivo quantification of human neurofibrillary tangles. J Nucl Med, <b>57<\/b>:1599-1606, 2016.","DOI":"10.2967\/jnumed.115.171678"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Pascoal TA, Shin M, Kang MS, <i>et al<\/i>. In vivo quantification of neurofibrillary tangles with [<sup>18<\/sup>F]MK-6240. Alzheimers Res Ther, <b>10<\/b>:74, 2018.","DOI":"10.1186\/s13195-018-0402-y"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Betthauser TJ, Cody KA, Zammit MD, <i>et al<\/i>. In vivo characterization and quantification of neurofibrillary tau PET radioligand <sup>18<\/sup>F-MK-6240 in humans from Alzheimer disease dementia to young controls. J Nucl Med, <b>60<\/b>:93-99, 2019.","DOI":"10.2967\/jnumed.118.209650"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Lohith TG, Bennacef I, Vandenberghe R, <i>et al<\/i>. Brain imaging of Alzheimer dementia patients and elderly controls with <sup>18<\/sup>F-MK-6240, a PET tracer targeting neurofibrillary tangles. J Nucl Med, <b>60<\/b>:107-114, 2019.","DOI":"10.2967\/jnumed.118.208215"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Pascoal TA, Therriault J, Benedet AL, <i>et al<\/i>. <sup>18<\/sup>F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain, <b>143<\/b>:2818-2830, 2020.","DOI":"10.1093\/brain\/awaa180"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Aguero C, Dhaynaut M, Normandin MD, <i>et al<\/i>. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta Neuropathol Commun, <b>7<\/b>:37, 2019.","DOI":"10.1186\/s40478-019-0686-6"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Salinas C, Lohith TG, Purohit A, <i>et al<\/i>. Test-retest characteristic of [<sup>18<\/sup>F]MK-6240 quantitative outcomes in cognitively normal adults and subjects with Alzheimer\u2019s disease. J Cereb Blood Flow Metab, <b>40<\/b>:2179-2187, 2020.","DOI":"10.1177\/0271678X19887781"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol, <b>82<\/b>:239-259, 1991.","DOI":"10.1007\/BF00308809"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol, <b>112<\/b>:389-404, 2006.","DOI":"10.1007\/s00401-006-0127-z"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Gogola A, Minhas DS, Villemagne VL, <i>et al<\/i>. Direct Comparison of the Tau PET Tracers <sup>18<\/sup>F-Flortaucipir and <sup>18<\/sup>F-MK-6240 in Human Subjects. J Nucl Med, <b>63<\/b>:108-116, 2022.","DOI":"10.2967\/jnumed.120.254961"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Shuping JL, Matthews DC, Adamczuk K, <i>et al<\/i>. Development, initial validation, and application of a visual read method for [<sup>18<\/sup>F]MK-6240 tau PET. Alzheimers Dement (NY). <b>9<\/b>:e12372, 2023.","DOI":"10.1002\/trc2.12372"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Bennett RE, DeVos SL, Dujardin S, <i>et al<\/i>. Enhanced Tau Aggregation in the Presence of Amyloid \u03b2. Am J Pathol, <b>187<\/b>:1601-1612, 2017.","DOI":"10.1016\/j.ajpath.2017.03.011"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Vogel JW, Iturria-Medina Y, Strandberg OT, <i>et al<\/i>. Spread of pathological tau proteins through communicating neurons in human Alzheimer\u2019s disease. Nat Commun, <b>11<\/b>:2612, 2020.","DOI":"10.1101\/555821"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Crary JF, Trojanowski JQ, Schneider JA, <i>et al<\/i>. Primary age-related tauopathy (PART):a common pathology associated with human aging. Acta Neuropathol, <b>128<\/b>:755-766, 2014.","DOI":"10.1007\/s00401-014-1349-0"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Krishnadas N, Dor\u00e9 V, Groot C, <i>et al<\/i>. Mesial temporal tau in amyloid-\u03b2-negative cognitively normal older persons. Alzheimers Res Ther, <b>14<\/b>:51, 2022.","DOI":"10.1186\/s13195-022-00993-x"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Krishnadas N, Huang K, Schultz SA, <i>et al<\/i>. Visually Identified Tau <sup>18<\/sup>F-MK6240 PET Patterns in Symptomatic Alzheimer\u2019s Disease. J Alzheimers Dis, <b>88<\/b>:1627-1637, 2022.","DOI":"10.3233\/JAD-215558"},{"key":"66","unstructured":"66. Villemagne VL, Dor\u00e9 V, Bourgeat P, <i>et al<\/i>. The Tau MeTeR composites for the generation of continuous and categorical measures of tau deposits in the brain. J Mol Med Ther, <b>1<\/b>:25-32, 2017."},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Harrison TM, Ward TJ, Murphy A, <i>et al<\/i>. Optimizing quantification of MK6240 tau PET in unimpaired older adults. Neuroimage, <b>265<\/b>:119761, 2023.","DOI":"10.1016\/j.neuroimage.2022.119761"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Yamao T, Miwa K, Wagatsuma K, <i>et al<\/i>. Centiloid scale analysis for <sup>18<\/sup>F-THK5351 PET imaging in Alzheimer\u2019s disease. Physica medica, <b>82<\/b>:249-254, 2021.","DOI":"10.1016\/j.ejmp.2021.02.017"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Mintun MA, Lo AC, Duggan Evans C, <i>et al<\/i>. Donanemab in Early Alzheimer\u2019s Disease. N Engl J Med, <b>384<\/b>:1691-1704, 2021.","DOI":"10.1056\/NEJMoa2100708"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Rafii MS, Sperling RA, Donohue MC, <i>et al<\/i>. The AHEAD 3-45 Study:Design of a prevention trial for Alzheimer\u2019s disease. Alzheimers Dement, <b>19<\/b>:1227-1233, 2023.","DOI":"10.1002\/alz.12748"}],"container-title":["FUKUSHIMA JOURNAL OF MEDICAL SCIENCE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/69\/2\/69_2023-08\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T04:45:27Z","timestamp":1691815527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/69\/2\/69_2023-08\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.5387\/fms.2023-08","relation":{},"ISSN":["0016-2590","2185-4610"],"issn-type":[{"value":"0016-2590","type":"print"},{"value":"2185-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"2023-08"}}